Loading…
Post hoc analysis shows improvement over Omalizumab.
Cue Biopharma, Inc. (Nasdaq: CUE) announced results from its Phase 2 study of CUE-221 in patients with Chronic Spontaneous Urticaria (CSU). The study showed a 60% complete hives resolution twelve weeks off treatment at a 4 Mg/Kg dose of CUE-221.
The 60% resolution rate for CUE-221 at 4 Mg/Kg represents a notable improvement over the 24% rate observed with Omalizumab. The study's findings suggest a potential advantage for CUE-221 in treating CSU.
Cue Biopharma has a free float of 2,607,636 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.